These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 16566432)

  • 41. Vaccine cell substrates: bovine and porcine virus considerations.
    Wessman SJ
    Dev Biol (Basel); 2006; 123():273-80; discussion 291-308. PubMed ID: 16566453
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Animal-free culture process for manufacture of viral vaccines: process validation and regulatory perspectives.
    Pierard I; Mareschal JC; Gonze MM; Duchêne M
    Dev Biol (Basel); 2006; 123():283-90; discussion 291-308. PubMed ID: 16566454
    [No Abstract]   [Full Text] [Related]  

  • 43. Quality control of bovine serum used for vaccine production.
    Mareschal JC
    Dev Biol Stand; 1999; 99():61-8. PubMed ID: 10404877
    [No Abstract]   [Full Text] [Related]  

  • 44. Isolation and culture of preadipocytes from rodent white adipose tissue.
    Hausman DB; Park HJ; Hausman GJ
    Methods Mol Biol; 2008; 456():201-19. PubMed ID: 18516563
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Strategies of constructing recombinant vaccines.
    Sałamaszyńska-Guz A; Klimuszko D
    Pol J Vet Sci; 2009; 12(1):133-9. PubMed ID: 19459451
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mucosal immunization with a urease B DNA vaccine induces innate and cellular immune responses against Helicobacter pylori.
    Hatzifoti C; Roussel Y; Harris AG; Wren BW; Morrow JW; Bajaj-Elliott M
    Helicobacter; 2006 Apr; 11(2):113-22. PubMed ID: 16579841
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prime-boost vaccination using DNA and whole inactivated virus vaccines provides limited protection against virulent feline immunodeficiency virus.
    Dunham SP; Bruce J; Klein D; Flynn JN; Golder MC; MacDonald S; Jarrett O; Neil JC
    Vaccine; 2006 Nov; 24(49-50):7095-108. PubMed ID: 17049683
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Plasmid DNA and viral vector-based vaccines for the treatment of cancer.
    Anderson RJ; Schneider J
    Vaccine; 2007 Sep; 25 Suppl 2():B24-34. PubMed ID: 17698262
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Biotechnology and DNA vaccines for aquatic animals.
    Kurath G
    Rev Sci Tech; 2008 Apr; 27(1):175-96. PubMed ID: 18666487
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The International Liaison Committee on Resuscitation (ILCOR) consensus on science with treatment recommendations for pediatric and neonatal patients: pediatric basic and advanced life support.
    International Liaison Committee on Resuscitation
    Pediatrics; 2006 May; 117(5):e955-77. PubMed ID: 16618790
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Progress on baculovirus-derived influenza vaccines.
    Cox MM
    Curr Opin Mol Ther; 2008 Feb; 10(1):56-61. PubMed ID: 18228182
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Modifying professional antigen-presenting cells to enhance DNA vaccine potency.
    Hung CF; Yang M; Wu TC
    Methods Mol Med; 2006; 127():199-220. PubMed ID: 16988456
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [The origin of informed consent].
    Mallardi V
    Acta Otorhinolaryngol Ital; 2005 Oct; 25(5):312-27. PubMed ID: 16602332
    [TBL] [Abstract][Full Text] [Related]  

  • 54. DNA issues.
    Meulien P
    Dev Biol Stand; 1998; 93():57-60. PubMed ID: 9737377
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Preclinical and clinical progress of particle-mediated DNA vaccines for infectious diseases.
    Fuller DH; Loudon P; Schmaljohn C
    Methods; 2006 Sep; 40(1):86-97. PubMed ID: 16997717
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Co-inoculation of DNA and protein vaccines induces antigen-specific T cell suppression.
    Kang Y; Jin H; Zheng G; Du X; Xiao C; Zhang X; Geng S; Li X; Wang J; Chen A; Wang B
    Biochem Biophys Res Commun; 2007 Feb; 353(4):1034-9. PubMed ID: 17204242
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecular adjuvants for malaria DNA vaccines based on the modulation of host-cell apoptosis.
    Bergmann-Leitner ES; Leitner WW; Duncan EH; Savranskaya T; Angov E
    Vaccine; 2009 Sep; 27(41):5700-8. PubMed ID: 19576940
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Elective termination of pregnancy after vaccination reported to the Vaccine Adverse Event Reporting System (VAERS): 1990-2006.
    Chang S; Ball R; Braun MM
    Vaccine; 2008 May; 26(19):2428-32. PubMed ID: 18406499
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [New advances in clinical trials of cancer vaccines].
    Peng F; Wei YQ
    Ai Zheng; 2006 Aug; 25(8):1059-62. PubMed ID: 16965694
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunogenicity and protective efficacy of Semliki forest virus replicon-based DNA vaccines encoding goatpox virus structural proteins.
    Zheng M; Jin N; Liu Q; Huo X; Li Y; Hu B; Ma H; Zhu Z; Cong Y; Li X; Jin M; Zhu G
    Virology; 2009 Aug; 391(1):33-43. PubMed ID: 19559453
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.